Smoking and fatty liver disease in rural therapeutic area residents

Aim: Evaluate the relationship of Smoking with fatty liver disease (FLD) of various etiologies.Materials and Methods: Out of1568 residents of the rural therapeutic area agreed to participate in the study of 1123 residents of the rural medical area with negative markers of hepatitis B and / or C. The survey included the collection of anamnesis for smoking and alcohol consumption. An objective, laboratory (complete blood count, biochemical liver function tests) and instrumental examination, including ultrasound examination of the abdominal organs, were carried out.Results: Non-alcoholic fatty liver disease (NAFLD) was detected in 247 (22.0%) people, alcoholic liver disease (ALD) — in 276 (24.6%) (p>0.05). 542 people smoked of the surveyed. Among patients with NAFLD, Smoking was 20.2%, their Smoking experience was 35.1±11.5 years, and the Smoking index was 24.5±10.9. Among patients with ALP, Smoking is higher-93.1% (p<0.05), Smoking experience is less — 29.5±9.8 years (p<0.05), as is the Smoking index of 21.8±7.7 (p<0.05). Among smokers, 56.8% had FLD, 83.8% of them were of alcoholic etiology, and 16.2% were non — alcoholic (p<0.05). Among non-smokers, compared with smokers, FLD was detected less frequently — in 37.2% of people (p<0.05), of which alcohol etiology — in 8.8% (p<0.05), non — alcoholic-in 91.2% (p<0.05).Conclusion: In the rural therapeutic area, 93.1% of ALD sufferers smoke, and 20.2% of NAFLD patients smoke (p<0.05). In patients with NAFLD, the duration of smoking was longer (35.1 ± 11.5) than in patients with ALD — 29.5 ± 9.8 years (p <0.05); the smoking index was 24.5 ± 10.9 and 21.8 ± 7.7 pack-years (p<0.05), respectively. In smokers, FLD was more common (56.8%) than in non-smokers (37.2%) (p<0.05). FLD in smokers was of alcoholic etiology more often (83.8%) than non-alcoholic (16.2%) (p<0.05), in non-smokers non-alcoholic etiology prevailed (91.2%) (p<0.05).

Download Full-text

Correlation Between Point Shear Wave Elastography and Liver Function Tests as A Predictor of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

10.53350/pjmhs211571936 ◽

2021 ◽

Vol 15 (7) ◽

pp. 1936-1939

Author(s):

Shahla Mohammed Saeed Rasul ◽

Ali Khalaf Salim ◽

Hiwa Abubakr Hussein

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Liver Function ◽

Fatty Liver ◽

Shear Wave ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Fibrosis Score ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Background: Nowadays, generating shear waves and simulation of the liver tissue is done using point shear-wave elastographic (pSWE) techniques which uess acoustic radiation force impulse (ARFI). Objective: This study aimed to evaluate the correlation between pSWE and liver function tests (LFTs) to predict liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods: It was a cross sectional study conducted in an Ultrasound Clinic in Suleymaniya city. The duration of the study was from 1st of November, 2018 to 30th of June, 2019 which conducted on 50 NAFLD patients. After confirming NAFLD diagnosis, the patients were referred to Ultrasound Clinic to go under pSWE test. Results: The data showed that the mean PSWE of NAFLD patient was 4.12±0.87 Kpa; and 18% of them had high PSWE (> 4.6). Elastography fibrosis score was distributed to F0 (82%), F1 (6%), F2 (8%) and F3 (4%). There was a significant association between high APRI and high Aspartate Aminotransferase/Alanine Aminotransferase(AST/ALT) ratio (p=0.04). There was also a highly significant association between elastography fibrosis score and APRI fibrosis score among NAFLD patients (p<0.001). Conclusion: This study showed that the pSWE is a valuable noninvasive diagnostic technique for predicting liver fibrosis among NAFLD patients and there is significant correlation between APRI and pSWE scores. Keywords: Non-alcoholic fatty liver disease, Point shears wave elastography, Liver fibrosis.

Download Full-text

Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial

Egyptian Liver Journal ◽

10.1186/s43066-019-0001-z ◽

2019 ◽

Vol 9 (1) ◽

Author(s):

Amir Mohammad Kazemifar ◽

Ali Akbar Shafikhani ◽

Elaheh HajiNoormohammadi ◽

Zahra Azarion ◽

Aliakbar Hajiaghamohammadi

Keyword(s):

Helicobacter Pylori ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Intervention Group ◽

Liver Function Tests ◽

Double Blind ◽

Alcoholic Fatty Liver ◽

Before And After ◽

Alcoholic Fatty Liver Disease

Abstract Background and objective The correlation between the eradication of Helicobacter pylori (HP) and non-alcoholic fatty liver disease (NAFLD) is a controversial one. The aim of this study is to investigate the effect of Helicobacter pylori treatment on liver function tests and lipid profiles and to compare its effects with exercise therapy and diet alone. Method This was a double-blind randomized clinical trial conducted at Qazvin University of Medical Sciences. One hundred patients with NAFLD having a positive test for urea breath testing were randomly assigned into one of the intervention and comparison groups. The diet and physical activity program were given to two groups of patients for 8 weeks, three sessions per week. In addition to the above therapy, the patients in the intervention group also received HP treatment for 2weeks. The data corresponding to anthropometric and clinical features before and after the intervention were collected in both groups and compared using appropriate statistical methods. Results After the treatment interventions, the variables of weight, BMI, blood glucose, triglyceride, AST, ALT, total cholesterol, and LDL-C were significantly decreased in both groups (p < .05). In the between-group comparisons, only ALT was significantly lower in the intervention group (HP) (p < .05). Conclusion Findings of this study showed that the eradication of Helicobacter pylori could significantly improve the ALT index, but it had no additional effect on changes in metabolic indicators. Trial registration Registration number: IRCT2015042020951N2 Name of trial registry: The study of treatment of Helicobacter pylori in improvement of non-alcoholic fatty liver disease The date of registration: 2015-05-12 Where the full trial protocol can be accessed: https://fa.irct.ir/trial/18489

Download Full-text

NAFLD (Non‐Alcoholic Fatty Liver Disease) in non‐diabetic subjects: independent relationship of dietary profile and Bright Liver Score (BLS) with the severity of systolic heart function impairment

The FASEB Journal ◽

10.1096/fasebj.27.1_supplement.1067.7 ◽

2013 ◽

Vol 27 (S1) ◽

Author(s):

Guglielmo M. Trovato ◽

Daniela Catalano ◽

G. Fabio Martines ◽

Francesco Carcò ◽

Davide Coco ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Heart Function ◽

Alcoholic Fatty Liver ◽

Function Impairment ◽

Relationship Of ◽

Alcoholic Fatty Liver Disease

Download Full-text

Su1448 Relationship of Non-Alcoholic Fatty Liver Disease to Colorectal Neoplasia

Gastrointestinal Endoscopy ◽

10.1016/j.gie.2012.03.873 ◽

2012 ◽

Vol 75 (4) ◽

pp. AB335-AB336

Author(s):

Jue Yong Lee ◽

Ja Won Kim ◽

Sun Pil Choi ◽

Jong Ho Park ◽

Yeon Ho Joo

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Colorectal Neoplasia ◽

Alcoholic Fatty Liver ◽

Relationship Of ◽

Alcoholic Fatty Liver Disease

Download Full-text

Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph17103518 ◽

2020 ◽

Vol 17 (10) ◽

pp. 3518

Author(s):

Dariusz Narankiewicz ◽

Josefina Ruiz-Nava ◽

Veronica Buonaiuto ◽

María Isabel Ruiz-Moreno ◽

María Dolores López-Carmona ◽

...

Keyword(s):

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Mediterranean Population ◽

Alcoholic Fatty Liver ◽

Metabolic Phenotypes ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

The aim of this study was to analyze the utility of liver function tests (LFT) and fatty liver index (FLI), a surrogate marker of non-alcoholic fatty liver disease, in the categorization of metabolic phenotypes in a Mediterranean population. A cross-sectional study was performed on a random representative sample of 2233 adults assigned to a health center in Málaga, Spain. The metabolic phenotypes were determined based on body mass index (BMI) categorization and the presence or absence of two or more cardiometabolic abnormalities (high blood pressure, low high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, pre-diabetes) or type 2 diabetes. No difference was observed between metabolically healthy and metabolically abnormal phenotypes on LFT. The mean FLI of the population was 41.1 ± 28.6. FLI was significantly higher (p < 0.001) in the metabolically abnormal phenotypes in all BMI categories. The proportion of individuals with pathological FLI (≥60) was significantly higher in the metabolically abnormal overweight and obese phenotypes (p < 0.001). On a multivariate model adjusted for sex, age, and waist circumference, a significant correlation was found between pathological FLI and metabolically abnormal phenotypes in the overweight and obese BMI categories. Area under the curve (AUC) of FLI as a biomarker was 0.76, 0.74, and 0.72 for the metabolically abnormal normal-weight, overweight, and obese groups, respectively. Liver biochemistry is poorly correlated with metabolic phenotypes. Conversely, a good correlation between FLI, as a marker of non-alcoholic fatty liver disease (NAFLD), and metabolically abnormal phenotypes in all BMI ranges was found. Our study suggests that FLI may be a useful marker for characterizing metabolically abnormal phenotypes in individuals who are overweight or obese.

Download Full-text

The pathogenesis of non-alcoholic fatty liver disease is closely related to the metabolic syndrome components

Romanian Journal of Diabetes Nutrition and Metabolic Diseases ◽

10.2478/v10255-012-0037-x ◽

2012 ◽

Vol 19 (3) ◽

pp. 311-321 ◽

Cited By ~ 1

Author(s):

Daniela Maria Hurjui ◽

Otilia Niţă ◽

Lidia Iuliana Graur ◽

Dana Ştefana Popescu ◽

Laura Mihalache ◽

...

Keyword(s):

Metabolic Syndrome ◽

Liver Disease ◽

Fatty Liver ◽

Chronic Inflammation ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Alcoholic Fatty Liver ◽

The Metabolic Syndrome ◽

Secondary Injuries ◽

Alcoholic Fatty Liver Disease

Abstract Non-alcoholic fatty liver disease (NAFLD) is closely associated with all features ofthe metabolic syndrome (MS). This strongly supports the notion that NAFLD may bethe hepatic manifestation of the MS. NAFLD is currently the most common cause ofabnormal liver function tests and affects approximatively 15-25% of the generalpopulation. NAFLD covers a spectrum of liver disease, from steatosis to nonalcoholicsteatohepatitis (NASH) and cirrhosis. Insulin resistance (IR) has centraletiologic roles in the development of MS and NAFLD, usually related to obesity. MSis frequently associated with chronic inflammation, having as principal mediatorsthe adipocytokines and free fatty acids (FFA), but also CRP, TNF-a and IL-6.Chronic inflammation results in more IR and lipolysis of adipose tissue triglyceridestores, in enhanced hepatic glucose and VLDL production. The steatotic liver isthought to be vulnerable to secondary injuries including adipocytokines,mitochondrial dysfunctions, oxidative stress which lead to hepatocellularinflammation and fibrosis.

Download Full-text